These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1381 related items for PubMed ID: 25701353

  • 1. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
    Zeng X, Zhao H, Li Y, Fan J, Sun Y, Wang S, Wang Z, Song P, Ju D.
    Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
    [Abstract] [Full Text] [Related]

  • 2. Hsp90 inhibitor, BIIB021, induces apoptosis and autophagy by regulating mTOR-Ulk1 pathway in imatinib-sensitive and -resistant chronic myeloid leukemia cells.
    He W, Ye X, Huang X, Lel W, You L, Wang L, Chen X, Qian W.
    Int J Oncol; 2016 Apr; 48(4):1710-20. PubMed ID: 26892093
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Antitumor efficacy of arsenic/interferon in preclinical models of chronic myeloid leukemia resistant to tyrosine kinase inhibitors.
    El Eit R, Itani AR, Nassar F, Rasbieh N, Jabbour M, Santina A, Zaatari G, Mahon FX, Bazarbachi A, Nasr R.
    Cancer; 2019 Aug 15; 125(16):2818-2828. PubMed ID: 31034603
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Novel Acylguanidine Derivatives Targeting Smoothened Induce Antiproliferative and Pro-Apoptotic Effects in Chronic Myeloid Leukemia Cells.
    Chiarenza A, Manetti F, Petricci E, Ruat M, Naldini A, Taddei M, Carraro F.
    PLoS One; 2016 Aug 15; 11(3):e0149919. PubMed ID: 26934052
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Distinct Dasatinib-Induced Mechanisms of Apoptotic Response and Exosome Release in Imatinib-Resistant Human Chronic Myeloid Leukemia Cells.
    Liu J, Zhang Y, Liu A, Wang J, Li L, Chen X, Gao X, Xue Y, Zhang X, Liu Y.
    Int J Mol Sci; 2016 Apr 08; 17(4):531. PubMed ID: 27070592
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Blockade of the interaction between Bcr-Abl and PTB1B by small molecule SBF-1 to overcome imatinib-resistance of chronic myeloid leukemia cells.
    Elgehama A, Chen W, Pang J, Mi S, Li J, Guo W, Wang X, Gao J, Yu B, Shen Y, Xu Q.
    Cancer Lett; 2016 Mar 01; 372(1):82-8. PubMed ID: 26721204
    [Abstract] [Full Text] [Related]

  • 15. A novel tubulin polymerization inhibitor, MPT0B206, downregulates Bcr-Abl expression and induces apoptosis in imatinib-sensitive and imatinib-resistant CML cells.
    Chen CW, Lee YL, Liou JP, Liu YH, Liu CW, Chen TY, Huang HM.
    Apoptosis; 2016 Sep 01; 21(9):1008-18. PubMed ID: 27344662
    [Abstract] [Full Text] [Related]

  • 16. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
    Burchert A, Wang Y, Cai D, von Bubnoff N, Paschka P, Müller-Brüsselbach S, Ottmann OG, Duyster J, Hochhaus A, Neubauer A.
    Leukemia; 2005 Oct 01; 19(10):1774-82. PubMed ID: 16136169
    [Abstract] [Full Text] [Related]

  • 17. Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition.
    Mitchell R, Hopcroft LEM, Baquero P, Allan EK, Hewit K, James D, Hamilton G, Mukhopadhyay A, O'Prey J, Hair A, Melo JV, Chan E, Ryan KM, Maguer-Satta V, Druker BJ, Clark RE, Mitra S, Herzyk P, Nicolini FE, Salomoni P, Shanks E, Calabretta B, Holyoake TL, Helgason GV.
    J Natl Cancer Inst; 2018 May 01; 110(5):467-478. PubMed ID: 29165716
    [Abstract] [Full Text] [Related]

  • 18. Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms.
    Lan X, Zhao C, Chen X, Zhang P, Zang D, Wu J, Chen J, Long H, Yang L, Huang H, Carter BZ, Wang X, Shi X, Liu J.
    J Hematol Oncol; 2016 Nov 25; 9(1):129. PubMed ID: 27884201
    [Abstract] [Full Text] [Related]

  • 19. Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.
    Lee J, Shen P, Zhang G, Wu X, Zhang X.
    Biomed Pharmacother; 2013 Mar 25; 67(2):157-63. PubMed ID: 23201011
    [Abstract] [Full Text] [Related]

  • 20. HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation.
    Kim SJ, Jung KH, Yan HH, Son MK, Fang Z, Ryu YL, Lee H, Lim JH, Suh JK, Kim J, Lee S, Hong S, Hong SS.
    Oncotarget; 2015 Jan 30; 6(3):1507-18. PubMed ID: 25483100
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 70.